71 Participants NeededMy employer runs this trial

[18F]FPyQCP PET Imaging for Colorectal Cancer

EP
JM
Overseen ByJamie MacKay, MD, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Who Is on the Research Team?

SR

Steven Rowe, MD

Principal Investigator

University of Texas Southwestern Medical Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I am between 18 and 79 years old and able to give consent.
I have been diagnosed with CRC, GC, PDAC, ILC, or EOC.
5. Women of childbearing potential (WOCBP) should have a negative serum test at screening (Visit 1) and a negative urine pregnancy test at the PET/CT imaging visit (Visit 2) prior to \[18F\]FPyQCP administration.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive [18F]FPyQCP followed by PET/CT imaging

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

42 days

What Are the Treatments Tested in This Trial?

Interventions

  • [18F]FPyQCP

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: [18F]FPyQCP PET/CTExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Blue Earth Diagnostics

Lead Sponsor

Trials
43
Recruited
3,100+

Medpace, Inc.

Industry Sponsor

Trials
98
Recruited
30,400+

Dr. August J. Troendle

Medpace, Inc.

Chief Executive Officer since 1992

MD from the University of Maryland, School of Medicine; MBA from Boston University

Dr. Reinilde Heyrman

Medpace, Inc.

Chief Medical Officer since 2017

MD